BELOTECAN HYDROCHLORIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C25H27N3O4.ClH
Molecular Weight	469.961
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=C(CCNC(C)C)C5=CC=CC=C5N=C34)C2=O

InChI

InChIKey=SJKBXKKZBKCHET-UQIIZPHYSA-N

InChI=1S/C25H27N3O4.ClH/c1-4-25(31)19-11-21-22-17(12-28(21)23(29)18(19)13-32-24(25)30)15(9-10-26-14(2)3)16-7-5-6-8-20(16)27-22;/h5-8,11,14,26,31H,4,9-10,12-13H2,1-3H3;1H/t25-;/m0./s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9875499

Belotecan is a semisynthetic analogue of camptothecin containing a 2-(N-isopropylamino) ethyl group linkage at position C-7 of the camptothecin ring. It stabilizes the complex formed between topoisomerase I and DNA, thereby preventing the religation of DNA breaks. This leads to an inhibition of DNA replication and triggers apoptotic cell death. Belotecan was approved in Korea under the name Camtobell for the treatment of patients with ovarian and small cell lung cancers.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
DNA topoisomerase 1 16 Target ID: P11387\|\|\|Q9UJN0 Gene ID: 7150.0 Gene Symbol: TOP1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/9875499	Inhibitor 8297		0.275 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Ovarian cancer 157 Sources: http://www.kpbma.or.kr/attach/2016%20%EC%A0%9C%EC%95%BD%ED%98%91%ED%9A%8C%20%EC%98%81%EB%AC%B8%EB%94%94%EB%A0%89%ED%86%A0%EB%A6%AC_%EB%82%B4%EC%A7%80%EC%B5%9C%EC%A2%85.pdf	Primary		Approved 8429	CAMTOBELL Approved Use Ovarian cancer, SCLC Launch Date 2003
Small-cell lung cancer 41 Sources: http://www.kpbma.or.kr/attach/2016%20%EC%A0%9C%EC%95%BD%ED%98%91%ED%9A%8C%20%EC%98%81%EB%AC%B8%EB%94%94%EB%A0%89%ED%86%A0%EB%A6%AC_%EB%82%B4%EC%A7%80%EC%B5%9C%EC%A2%85.pdf	Primary		Approved 8429	CAMTOBELL Approved Use Ovarian cancer, SCLC Launch Date 2003

PubMed

Title	Date	PubMed
CKD-602. Chong Kun Dang.	2003 Dec	14763132
Embryotoxic effects of CKD-602, a new camptothecin anticancer agent, in rats.	2005 May-Jun	15808800
CKD-602, a camptothecin derivative, inhibits proliferation and induces apoptosis in glioma cell lines.	2009 Jun	19424618
Decreased urinary secretion of belotecan in folic acid-induced acute renal failure rats due to down-regulation of Oat1 and Bcrp.	2009 Oct	19552531
Efficacy and toxicity of belotecan with and without cisplatin in patients with recurrent ovarian cancer.	2010 Jun	19745693

Patents

Sample Use Guides

In Vivo Use Guide

Small cell lung cancer: 0.5mg/m2/day for day 1 to 4. Ovarian cancer: 0.5mg/m2 IV days 1, 2, 3, 4, 5 of each 21 day cycle until 6 cycle or disease progression.

Route of Administration: Intravenous

In Vitro Use Guide

In a cell viability assay, human glioblastoma cell lines (U87 MG, U251 MG, U343 MG, LN229) were plated in 96-well plates at a density of 2x10(3) cells/well (100 ul). In each experimental set, cells were plated in quadruplicate and were treated with different concentrations (0.05, 0.1, 0.2, 0.5, 1, 2, 5 uM) of belotecan for 24, 48 and 72 h. The IC50 values were 84.66 nM for U87 MG cells, 29.13 nM for U343 MG, 14.57 nM for U251 MG cells and 9.07 nM for LN229 cells at 48 h after treatment.

Name

Type

Language

BELOTECAN HYDROCHLORIDE

Official Name

English

BELOTECAN HYDROCHLORIDE [MI]

Common Name

English

BELOTECAN HCL

Common Name

English

BELOTECAN HYDROCHLORIDE [MART.]

Common Name

English

BELOTECAN HYDROCHLORIDE [USAN]

Common Name

English

1H-PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLINE-3,14(4H,12H)-DIONE,4-ETHYL-4-HYDROXY-11(2-((1METHYLETHYL)-MONOHYDROCHLORIDE, (4S)-

Common Name

English

(4S)-4-ETHYL-4-HYDROXY-11-(2-((1-METHYLETHYL)AMINO)ETHYL)-1,12-DIHYDRO-14H-PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLINE-3,14(4H)-DIONEHYDRODCHLORIDE

Common Name

English

CKD-602

Code

English

Belotecan hydrochloride [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C2843